Clinical trial
Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant…
NCT00418080 · University of L'Aquila, Other · Completed
Key facts
| NCT number | NCT00418080 |
|---|---|
| Title | Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy |
| Official title | The Role of HER Receptor Family as Indicator of Prognosis and Drug Responsiveness in Locally Advanced Prostate Cancer |
| Lead sponsor | University of L'Aquila, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | bicalutamide |
| Enrollment | 86 |
| Start date | Apr 1, 2002 |
| Completion | Dec 1, 2006 |
| First posted | Jan 4, 2007 |
| Last update posted | Oct 8, 2007 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: